Buprenorphine/Naloxone

Limits on what this shows

• Null/negative findings: No human study was found measuring mitochondrial function directly in buprenorphine-treated patients. A separate human comparative study (Elman et al. 2020, buprenorphine vs methadone, n=58) found no adverse metabolic-syndrome signal associated with buprenorphine and did not investigate mitochondrial endpoints directly; it is cited here as indirect reassurance, not as a mitochondrial null result (see ATP production entry).
• At-risk subgroups: Not established in humans. The in vitro concentrations used in the neuronal and breast-cancer-cell studies were not confirmed to be at or below typical clinical plasma levels for this review.

Regulatory status

Not addressed in FDA labeling; no mitochondrial-toxicity warning.

Population evidence

Berson et al. 2001, Journal of Hepatology (PMID 11281555), in vitro isolated rat liver mitochondria, microsomes, and primary hepatocytes: the paper's own title identifies a "major role of mitochondrial dysfunction versus metabolic activation" as the mechanism of experimental buprenorphine hepatotoxicity; the full abstract and quantitative dose-response data could not be independently retrieved this session (the publisher page returned no extractable content). Tanaka et al. 1985, Masui (Japanese Journal of Anesthesiology, PMID 2935653), in vitro isolated rat liver mitochondria: study directly titled around buprenorphine's effect on oxidative phosphorylation; this is a pre-DOI-era Japanese-language article and its content could not be retrieved through PubMed, Crossref, or a direct journal search this session, so only its existence, subject, and in vitro rat-mitochondria design are confirmed, not its direction of effect. Kugawa et al. 2004, Biological and Pharmaceutical Bulletin (PMID 15340216), in vitro NG108-15 neuronal hybrid cells: over-expressed Bcl-2 could not suppress buprenorphine-induced apoptosis occurring via the mitochondrial pathway. Kugawa et al. 2004, Life Sciences (PMID 15135650), in vitro MCF-7 human breast cancer cells: buprenorphine hydrochloride induced apoptosis-like cell death.

Mechanism

Mitochondria-mediated apoptotic signaling is implicated in the two Kugawa cell-culture studies; direct impairment of hepatocyte mitochondrial function (oxidative phosphorylation and/or bioenergetics) is implicated as the dominant mechanism in the Berson hepatotoxicity study, at the title/indexed level.

Counter-evidence held on record

All direct evidence is decades-old in vitro or isolated-organelle data. Nothing here establishes mitochondrial harm at standard human maintenance dosing, and this entry is not a basis for CoQ10 or other mitochondrial-support supplementation, for which no dosing evidence exists in this population. See Overlap map: Berson 2001 and Tanaka 1985 are both also cited under ATP production; do not count as independent confirmation there.

Limits on what this shows

• Null/negative findings: Total antioxidant capacity (TAC) showed no significant alteration in the Leventelis 2019 cohort despite the other marker changes, a real partial null worth preserving. The same study explicitly frames both methadone and buprenorphine maintenance as producing "less severe" oxidative stress than continued heroin use, i.e. the comparator that matters most for this population (active heroin use) shows a larger effect than either substitution therapy.
• At-risk subgroups: Heroin-dependent adults in approximately the first three months of buprenorphine maintenance. Not established for patients initiated on buprenorphine without prior heroin/IV opioid use, or for longer-term stable maintenance beyond three months.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Leventelis et al. 2019, Oxidative Medicine and Cellular Longevity, cross-sectional, n=71: 23 healthy controls, 48 opioid-maintenance patients (28 methadone, 20 buprenorphine, mean buprenorphine dose 16 mg/day) after three months of treatment for heroin dependence. Buprenorphine-maintenance-treatment (BMT) group versus controls: reduced glutathione (GSH) down 51%, erythrocyte catalase activity down 10% (significantly less severe than the methadone group's 22% reduction, p<0.05 between groups), plasma TBARS (lipid peroxidation) up 120%, plasma protein carbonyls up 34%; total antioxidant capacity (TAC) not significantly altered. Arezoomandan et al. 2022, Journal of Clinical Neuroscience (PMID 35533613): human study comparing methadone-maintenance, buprenorphine-maintenance, and healthy-control groups on inflammatory, oxidative-stress, and cognitive measures; existence and buprenorphine-specific cohort confirmed via bibliographic record, but full text was paywalled and returned no retrievable content through the DOI/ScienceDirect route tried this session, so effect sizes and direction for the buprenorphine subgroup specifically are not independently verified here. Leventelis et al. 2025, Clinical Nutrition ESPEN (PMID 39798867): randomized controlled trial of pomegranate juice in patients under medication for opioid-addiction treatment; title indicates the juice "ameliorates craving and oxidative stress," implying elevated baseline oxidative stress in this population, but the full text was not retrievable this session (PubMed individual-record page returned a bot-verification challenge) and it is not confirmed whether the cohort was buprenorphine-specific or mixed with methadone.

Mechanism

Not fully characterized at the molecular level in the sources reviewed. General plausibility comes from mitochondria-mediated cell stress documented in vitro for buprenorphine (see Mitochondrial burden entry and Overlap map) and from the broader literature on immune/inflammatory activation in substance use disorders, though neither is confirmed as the specific driver in the human cohort above.

Counter-evidence held on record

This is a bounded comparison against healthy, non-substance-using controls, not against untreated opioid use disorder; confounding by indication (Hard Rule 6) is not excluded, and the same evidence base indicates buprenorphine is associated with less oxidative stress than active heroin use, not more. Do not use this entry to justify indiscriminate antioxidant supplementation; no supplement dosing evidence exists in this population, and any antioxidant use should be discussed with the treating clinician.

Limits on what this shows

• Null/negative findings: None found for buprenorphine directly; no dedicated buprenorphine study exists to report a null result from.
• At-risk subgroups: None established for buprenorphine.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Nakhaee et al. 2024, Scientific Reports (PMID 38454098), cross-sectional, Kermanshah, Iran, April-December 2022: n=67 methadone-treatment (MT) patients (mean dose 40 mg/day; concurrent use of opium, opium plus tramadol, opium plus cannabis, or all three in various subgroups) versus n=62 lifestyle/diet-matched healthy controls; urinary trace elements measured by ICP-MS (97-103% recovery). Urinary copper was significantly lower in the MT group than controls (p<0.05).

Mechanism

Not established for methadone or buprenorphine specifically. This project's general mechanism screen (Step 1/2) found no chelation, gastric-pH, or renal-tubular-wasting pathway documented for buprenorphine or naloxone with any classical mineral. Reduced urinary excretion in a polysubstance-using population could reflect lower dietary copper intake rather than a drug-specific renal or absorptive effect, despite the study's attempt to match lifestyle and diet.

Counter-evidence held on record

This is class extrapolation from methadone, a full mu-opioid agonist with materially different receptor and pharmacokinetic properties than buprenorphine's partial agonism, studied in a polysubstance-using population with its own dietary confounds. It does not establish a buprenorphine effect, and no copper dosing recommendation follows. See Overlap map: shares its single source with Iron and Selenium below.

Limits on what this shows

• Null/negative findings: None found for buprenorphine directly. A search specifically for buprenorphine and iron, ferritin, hepcidin, or anemia (three separately phrased PubMed queries, plus a fourth query on opioid-class and iron/hepcidin that surfaced only unrelated restless-legs-syndrome treatment literature, where the direction runs the opposite way, i.e. iron deficiency causing a condition opioids are sometimes used to treat, not opioids depleting iron) returned no buprenorphine-specific or mechanistically relevant class-level hits beyond the Nakhaee methadone study above.
• At-risk subgroups: None established for buprenorphine.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Nakhaee et al. 2024, Scientific Reports (PMID 38454098), the same cross-sectional cohort described under Copper (n=67 methadone-treatment patients vs n=62 controls, urinary ICP-MS): urinary iron was significantly lower in the MT group than controls (p<0.05), following the same overall pattern reported for copper and selenium in this study.

Mechanism

Not established. No absorption-interference, renal-wasting, or GI-blood-loss mechanism is documented in the buprenorphine/naloxone label. Dietary confounding in a polysubstance-using population is a plausible alternative explanation, as with copper.

Counter-evidence held on record

Class extrapolation from methadone only; does not establish a buprenorphine effect on iron status, and no iron dosing recommendation follows. See Overlap map: shares its single source with Copper and Selenium.

Limits on what this shows

• Null/negative findings: The buprenorphine-naloxone-specific null finding (n=4) is itself the key counter-evidence in this entry and is reported here rather than omitted, though the subgroup is very small and likely underpowered to detect a real difference.
• At-risk subgroups: None established for buprenorphine specifically; the class-level (full-agonist) signal comes from heroin and other full-agonist opioid users, a different pharmacological group.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Gicquelais et al. 2020, Scientific Reports (PMID 33173098), cross-sectional, n=46 outpatient addiction-treatment patients, stool 16S rRNA sequencing. Groups: opioid agonists only (heroin/prescription opioids), n=5; agonist plus antagonist (buprenorphine-naloxone), n=4; antagonist only (naltrexone), n=6; neither, n=31. Agonist-only users showed reduced alpha diversity, fewer Bacteroides-dominant enterotypes, and lower abundance of Roseburia and Bilophila (butyrate- and bile-acid-metabolizing genera) compared with the "neither" group. The authors report explicitly that "there were no differences in gut microbiota features" between the buprenorphine-naloxone group, the naltrexone-only group, and the "neither" group.

Mechanism

Opioid-receptor-mediated effects on gut motility, mucosal immune function, and bacterial gene expression are documented broadly for full mu-agonists in animal models. Buprenorphine's partial mu-agonism and weak kappa-antagonist/delta-agonist activity offer a plausible pharmacological reason its gut effects could differ from full agonists, consistent with the null observed in its own subgroup.

Counter-evidence held on record

This entry is graded yellow to disclose a plausible class-level mechanism from full-agonist opioids, not because buprenorphine itself was shown to disrupt the microbiome; the one study to test buprenorphine-naloxone directly found no significant effect, on an admittedly small n=4 sample.

Limits on what this shows

• Null/negative findings: The FDA label's clinical-trial adverse-reaction tables report no hematologic adverse events for Suboxone sublingual film in its pivotal 16-week dose-controlled trial, a reassuring but indirect human data point, since routine trials do not necessarily report hemoglobin/hematocrit as a monitored efficacy or safety endpoint.
• At-risk subgroups: None established in humans.

Regulatory status

Not addressed in FDA labeling; the clinical-trial adverse-reaction tables in the current label (16-week dose-controlled trial) list no hematologic adverse reactions (anemia, hemoglobin, or hematocrit changes) among reported events.

Population evidence

Banerjee & Sarkar 1997, Folia Biologica (Krakow) (PMID 9643170), animal (mice): PubMed's own indexed description confirms the study "examined haematological parameters like total counts of red and white blood cells... haematocrit value and blood haemoglobin level" in buprenorphine-treated mice. The full abstract and directional findings could not be retrieved this session: the PubMed individual-record page returned a bot-verification challenge rather than content, and per-title lookups on both Semantic Scholar and OpenAlex returned repeated HTTP 429 rate-limit responses. This is disclosed as a tooling limitation, not a finding of no effect.

Mechanism

Not established. No hematologic mechanism (marrow suppression, hemolysis, or altered erythropoiesis) is documented in FDA labeling for buprenorphine or naloxone.

Counter-evidence held on record

This grade rests on confirming that a dedicated, drug-specific animal study exists and exactly what it measured, not on knowing its result; no directional claim of harm or benefit is made here. A future revision should re-attempt retrieval of the Banerjee & Sarkar 1997 findings once PubMed/Semantic Scholar/OpenAlex access is unrestricted.

Limits on what this shows

• Null/negative findings: Elman et al. 2020 (Scientific Reports, PMID 32221389), human, n=58 (26 buprenorphine, 32 methadone): found buprenorphine associated with a significantly lower rate of metabolic syndrome (34% vs 56% on methadone), higher HDL, and better insulin sensitivity than methadone, with no signal of adverse cardiometabolic derangement; the study did not measure cellular ATP or bioenergetics directly, so this is offered as indirect reassurance at the whole-body metabolic level, not as a direct ATP null result.
• At-risk subgroups: None established.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Tanaka et al. 1985, Masui (PMID 2935653), in vitro isolated rat liver mitochondria (the same study cited under Mitochondrial burden; see Overlap map): title and PubMed indexing confirm the study directly examined buprenorphine's effect on oxidative phosphorylation, but the pre-DOI-era, Japanese-language full text could not be retrieved through PubMed, Crossref, or direct journal search this session, so direction of effect (stimulation, inhibition, or no change) is not confirmed. Berson et al. 2001, Journal of Hepatology (PMID 11281555), in vitro rat liver mitochondria/hepatocytes (also cited under Mitochondrial burden): identifies mitochondrial dysfunction as the dominant mechanism of buprenorphine hepatotoxicity at the title/indexed level; ATP levels specifically were not confirmed as a directly reported quantitative endpoint in the material retrievable this session.

Mechanism

Oxidative phosphorylation is, by definition, the biochemical process of mitochondrial ATP synthesis, so a study titled around this endpoint is mechanistically on-topic; but without confirmed results, no direction of effect on ATP synthesis is claimed here.

Counter-evidence held on record

No human ATP or bioenergetic data exist for buprenorphine. This entry should not be read as evidence of an energy-production deficit at standard maintenance dosing and does not support CoQ10 or other ATP-targeted supplementation. See Overlap map: shares both supporting sources with Mitochondrial burden; do not count as independent confirmation across the two entries.